Literature DB >> 3127216

Mitomycin C-induced renal toxicity, a dose-dependent side effect?

J Verwey1, J de Vries, H M Pinedo.   

Abstract

Mitomycin C (MMC) has been known to be nephrotoxic since 1971. Whether this side effect was dose-dependent is unknown, while data on incidence are scanty. The presently-reported prospective study was initiated with the objective to obtain more data on these subjects. Forty-four patients treated with MMC entered the study, 37 were evaluable. All patients were subjected to extensive serial laboratory tests to study renal function and to detect hemolysis or coagulation disorders. The results were evaluated per cumulative dose level. One patient developed a lethal hemolytic uremic syndrome after 40 mg/m2 MMC. None of the laboratory tests predicted this side effect. None of the other patients developed renal toxicity, while all laboratory tests remained within normal ranges. All available literature on this subject was also reviewed. Based on the results of the present study, as well as on the literature review, it is concluded that MMC-related renal toxicity is a dose-dependent side effect, occurring at cumulative dose levels of 30 mg/m2 or more. The incidence is likely to be less than 10%. Predictive laboratory test could not be indicated.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3127216     DOI: 10.1016/0277-5379(87)90014-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

1.  The haemotoxicity of mitomycin in a repeat dose study in the female CD-1 mouse.

Authors:  Gemma Molyneux; Frances M Gibson; Edward C Gordon-Smith; Andrew M Pilling; Kai Chiu Liu; Sian Rizzo; Susan Sulsh; John A Turton
Journal:  Int J Exp Pathol       Date:  2005-12       Impact factor: 1.925

Review 2.  Toxicity patterns of cytotoxic drugs.

Authors:  Etienne Chatelut; Jean-Pierre Delord; Pierre Canal
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

3.  Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.

Authors:  S Serke; H Riess; H Oettle; D Huhn
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

4.  Curcumin reduces mitomycin C resistance in breast cancer stem cells by regulating Bcl-2 family-mediated apoptosis.

Authors:  Qian-Mei Zhou; Yang Sun; Yi-Yu Lu; Hui Zhang; Qi-Long Chen; Shi-Bing Su
Journal:  Cancer Cell Int       Date:  2017-09-26       Impact factor: 5.722

5.  Persister control by leveraging dormancy associated reduction of antibiotic efflux.

Authors:  Sweta Roy; Ali Adem Bahar; Huan Gu; Shikha Nangia; Karin Sauer; Dacheng Ren
Journal:  PLoS Pathog       Date:  2021-12-10       Impact factor: 6.823

6.  Synergistic effect of combinatorial treatment with curcumin and mitomycin C on the induction of apoptosis of breast cancer cells: a cDNA microarray analysis.

Authors:  Qian-Mei Zhou; Qi-Long Chen; Jia Du; Xiu-Feng Wang; Yi-Yu Lu; Hui Zhang; Shi-Bing Su
Journal:  Int J Mol Sci       Date:  2014-09-15       Impact factor: 5.923

7.  Diminishing the side effect of mitomycin C by using pH-sensitive liposomes: in vitro characterization and in vivo pharmacokinetics.

Authors:  Yi-Ping Fang; Pei-Yu Hu; Yaw-Bin Huang
Journal:  Drug Des Devel Ther       Date:  2018-01-15       Impact factor: 4.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.